N-terminal pro-brain natriuretic peptide as a biomarker for hypertensive disorders of pregnancy

American Journal of Perinatology

Volumn 27, Issue 4, 2010, Pages 313-319

  Moghbeli, Nazanin ^a   Srinivas, Sindhu K ^a,b   Bastek, Jamie ^a,b   Lu, Yun ^a,c   Putt, Mary E ^a,c   Cappola, Thomas P ^a   Elovitz, Michal A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Department of Obstetrics and Gynecology ^*  (United States)

^c Center for Clinical Epidemiology and Biostatistics   (United States)

Author keywords

Hypertensive disorders of pregnancy

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GESTATIONAL AGE; HOSPITAL ADMISSION; HUMAN; HYPOTHESIS; LABOR; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GESTATIONAL AGE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 77949754462     PISSN: 07351631     EISSN: 10988785     Source Type: Journal    
DOI: 10.1055/s-0029-1241735     Document Type: Article

References (27)

1. Chang J, Elam-Evans L D., Berg C J. et al. Pregnancy-related mortality surveillanceUnited States, 19911999. MMWR Surveill Summ 2003 52 1-8
2. ACOG Committee on Obstetric Practice American College of Obstetricians and Gynecologists. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Int J Gynaecol Obstet 2002 77 67-75
3. Irgens H U., Reisaeter L, Irgens L M., Lie R T. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ 2001 323 1213-1217
4. Ray J G., Vermeulen M J., Schull M J., Redelmeier D A. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 2005 366 1797-1803
5. Homer C S., Brown M A., Mangos G, Davis G K. Non-proteinuric pre-eclampsia: a novel risk indicator in women with gestational hypertension. J Hypertens 2008 26 295-302
6. Vatten L J., Skjaerven R. Is pre-eclampsia more than one disease? BJOG 2004 111 298-302
7. Gu Y, Lewis D F., Wang Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2008 93 260-266
8. Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 2008 51 970-975
9. Levine R J., Maynard S E., Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004 350 672-683
10. Levine R J., Lam C, Qian C et al, CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006 355 992-1005
11. Chaiworapongsa T, Espinoza J, Gotsch F et al. The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med 2008 21 25-40
12. Romero R, Nien J K., Espinoza J et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008 21 9-23
13. Stepan H, Geipel A, Schwarz F, Krämer T, Wessel N, Faber R. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol 2008 198 175, e1e6
14. Maisel A S., Krishnaswamy P, Nowak R M. et al, Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002 347 161-167
15. James S K., Lindahl B, Siegbahn A et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003 108 275-281
16. Fisher C, Berry C, Blue L, Morton J J., McMurray J. N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart 2003 89 879-881
17. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002 40 437-445
18. Pickering T G., Hall J E., Appel L J. et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005 111 697-716
19. Caritis S, Sibai B, Hauth J et al, National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Low-dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med 1998 338 701-705
20. Sibai B M. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 2004 103 (5 Pt 1) 981-991
21. Sibai B M. Biomarker for hypertension-preeclampsia: are we close yet? Am J Obstet Gynecol 2007 197 1-2
22. Herse F, Dechend R, Harsem N K. et al. Dysregulation of the circulating and tissue-based renin-angiotensin system in preeclampsia. Hypertension 2007 49 (3 suppl) 604-611
23. Benedetto C, Marozio L, Ciccone G et al. Synergistic effect of renin-angiotensin system and nitric oxide synthase genes polymorphisms in pre-eclampsia. Acta Obstet Gynecol Scand 2007 86 678-682
24. Shah D M. Preeclampsia: new insights. Curr Opin Nephrol Hypertens 2007 16 213-220
25. Tihtonen K M., Kööbi T, Vuolteenaho O, Huhtala H S., Uotila J T. Natriuretic peptides and hemodynamics in preeclampsia. Am J Obstet Gynecol 2007 196 328, e1e7
26. Fleming S M., OByrne L, Grimes H, Daly K M., Morrison J J. Amino-terminal pro-brain natriuretic peptide in normal and hypertensive pregnancy. Hypertens Pregnancy 2001 20 169-175
27. Resnik J L., Hong C, Resnik R et al. Evaluation of B-type natriuretic peptide (BNP) levels in normal and preeclamptic women. Am J Obstet Gynecol 2005 193 450-454